Please wait...

Quick Stats

Offers Claimed:


Downloaded Today:


Belbuca Prescription
view details
Generic Name: buprenorphine (oral/buccal) (BUE pre NOR feen (OR al / BUK al))
Brand Names: Belbuca
Belbuca (buprenorphine) is used for chronic pain management. Includes Belbuca side effects, interactions and indications.
Generic Name: buprenorphine (oral/buccal) (BUE pre NOR feen (OR al / BUK al))
Brand Names: Belbuca
Belbuca (buprenorphine) is used for chronic pain management. Includes Belbuca side effects, interactions and indications.
  • Select Your Prescription Settings
  • X
1 tablets of Belbuca 40 mg
  • Select Your Prescription Settings
  • X

Quick Stats

Offers Claimed: 60

Downloaded Today: 49

Set your location
for drug prices near you

Belbuca Coupons & Prices

Set your location
for drug prices near you

Enter your ZIP Code

Please wait while the prices are loaded...
Click here to try again.

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Belbuca Drug Information:

Belbuca buccal films contain Buprenorphine, an opioid medication. An opioid is sometimes called a narcotic. Belbuca buccal films are for around-the-clock treatment of moderate to severe chronic pain that is not controlled by other medicines. Belbuca is not for use on an as-needed basis for occasional pain. The Belbuca buccal film is placed between the gum and cheek where it adheres to the moist buccal mucosa to deliver the medicine as the film dissolves. Belbuca can slow or stop your breathing, and may be habit-forming. MISUSE OF OPIOID MEDICINE CAN CAUSE ADDICTION, OVERDOSE, OR DEATH, especially in a child or other person using the medicine without a prescription. Learn more

Belbuca Side Effects

Note: This document contains side effect information about buprenorphine. Some of the dosage forms listed on this page may not apply to the brand name Belbuca.

In Summary

Common side effects of Belbuca include: constipation and nausea. Other side effects include: dizziness, drowsiness, drug withdrawal, fatigue, headache, and vomiting. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to buprenorphine: film, tablet

Other dosage forms:

  • injection solution
  • intradermal implant
  • transdermal patch extended release

Buccal mucosa route (Film)

Addiction, Abuse, and MisuseBuprenorphine exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing buprenorphine, and monitor all patients regularly for the development of these behaviors or conditions.Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)To ensure that the benefits of opioid analgesics outweigh the risks of addiction, abuse and misuse, the Food and Drug Administration (FDA) has required a REMS for these products. Under the requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers. Healthcare providers are strongly encouraged to: complete a REMS-compliant education program, counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products, emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacists, and consider other tools to improve patient, household, and community safety.Life-Threatening Respiratory DepressionSerious, life-threatening, or fatal respiratory depression may occur with use of buprenorphine. Monitor for respiratory depression, especially during initiation of buprenorphine or following a dose increase. Misuse or abuse of buprenorphine by chewing, swallowing, snorting or injecting buprenorphine extracted from the buccal film will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death.Accidental ExposureAccidental exposure to even one dose of buprenorphine, especially by children, can result in a fatal overdose of buprenorphine.Neonatal Opioid Withdrawal SyndromeProlonged use of buprenorphine during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.Risks from Concomitant Use with Benzodiazepines or Other CNS DepressantsReserve concomitant prescribing of buprenorphine and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.

Along with its needed effects, buprenorphine (the active ingredient contained in Belbuca) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking buprenorphine:

Less common

  • Bladder pain
  • bloating or swelling of the face, arms, hands, lower legs, or feet
  • bloody or cloudy urine
  • blurred vision
  • cough producing mucus
  • diarrhea
  • difficult, burning, or painful urination
  • difficulty breathing
  • dizziness
  • fever
  • frequent urge to urinate
  • headache
  • loss of appetite
  • lower back or side pain
  • mouth or throat pain
  • nausea
  • nervousness
  • pale skin
  • pounding in the ears
  • rapid weight gain
  • slow or fast heartbeat
  • stomach pain
  • tightness in the chest
  • tingling of the hands or feet
  • troubled breathing with exertion
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • unusual weight gain or loss


  • Breakdown or tearing of the skin
  • chills
  • irregular heartbeat, recurrent
  • irritation, itching, pain, redness, swelling, tenderness, or warmth on the skin
  • unusual drowsiness, dullness, or feeling of sluggishness

Incidence not known

  • Agitation
  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
  • blurred vision
  • confusion
  • cough
  • darkening of the skin
  • difficulty swallowing
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • drowsiness
  • headache, severe and throbbing
  • hives, skin rash
  • irregular, fast, slow, or shallow breathing
  • mental depression
  • overactive reflexes
  • pale or blue lips, fingernails, or skin
  • pinpoint pupils
  • poor coordination
  • puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
  • relaxed and calm feeling
  • restlessness
  • shivering
  • sleepiness
  • talking or acting with excitement you cannot control
  • trembling or shaking
  • twitching
  • vomiting

Some side effects of buprenorphine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Back pain
  • chills
  • cough
  • difficulty having a bowel movement
  • hoarseness
  • painful or difficult urination
  • runny nose
  • sneezing
  • stuffy nose
  • trouble sleeping

Less common

  • Anxiety
  • back pain
  • bruise
  • decreased appetite
  • fall
  • feeling of warmth or heat
  • flushing or redness of the skin, especially on the face and neck
  • itching, skin rash
  • muscle aches or spams
  • pain or tenderness around eyes and cheekbones
  • sore throat


  • Lack or loss of strength
  • muscle or bone pain
  • neck pain
  • stomach discomfort
  • toothache

For Healthcare Professionals

Applies to buprenorphine: buccal film, compounding powder, injectable solution, subcutaneous solution extended release, subdermal implant, sublingual tablet, transdermal film extended release


The most common adverse reactions have included headache, insomnia, pain, signs and symptoms of withdrawal, nausea, constipation, application site pruritus, application site erythema, vomiting, hyperhidrosis, dizziness, somnolence, dry mouth, and application site rash.


Very common (10% or more): Insomnia (up to 28%), withdrawal syndrome (up to 24%), anxiety (up to 14%), depression (up to 13%)

Common (1% to 10%): Hostility, agitation, paranoid reaction, thinking abnormal, confusion

Uncommon (0.1% to 1%): Affect lability, depersonalization, libido decreased, nightmare, euphoric mood, psychosis, hallucination, euphoria

Very rare (less than 0.01%): Dependence, mood swings

Frequency not reported: Dreaming

Postmarketing reports: Neonatal withdrawal syndrome


Very common (10% or more): Rhinitis (up to 15%)

Common (1% to 10%): Cough increased, pharyngitis, upper respiratory tract infection, influenza, sinusitis, bronchitis, dyspnea, pharyngolaryngeal pain, hypoventilation, yawning

Uncommon (0.1% to 1%): Asthma aggravated, hiccups, hyperventilation, hypoxia, wheezing, apnea

Rare (less than 0.1%): Respiratory depression, respiratory failure

Postmarketing reports: Asphyxia


Very common (10% or more): Nausea (up to 23%), constipation (up to 14%), abdominal pain (11.7%), diarrhea (up to 10%)

Common (1% to 10%): Vomiting, dyspepsia, dry mouth, stomach discomfort, upper abdominal pain, flatulence

Rare (0.01% to 0.1%): Diverticulitis, dysphagia, ileus, heartburn

Very rare (less than 0.01%): Retching


Very common (10% or more): Application site pruritus (up to 15%), sweating (up to 13%), application site erythema (up to 10%)

Common (1% to 10%): Application site rash, application site irritation, hyperhidrosis, pruritus, rash, generalized pruritus

Uncommon (0.1% to 1%): Contact dermatitis, application site dermatitis, dry skin, facial edema, urticaria, pallor

Very rare (less than 0.01%): Pustules, vesicles

Frequency not reported: Injection site reaction, angioedema, application site edema


Very common (10% or more): Back pain (up to 16%)

Common (1% to 10%): Arthralgia, pain in extremity, muscle spasm, musculoskeletal pain, joint swelling, neck pain, myalgia, chest pain, leg cramps, bone pain, general spasm, muscle weakness, increased creatine phosphokinase (CPK)

Uncommon (0.1% to 1%): Muscle cramps, rigors, muscle spasm

Very rare (less than 0.01%): Muscle fasciculation, ear pain


Very common (10% or more): Pain (up to 26%), asthenia (up to 16%)

Common (1% to 10%): Chills, fever, accidental injury, fatigue, pyrexia, fall, malaise, tiredness, lethargy

Uncommon (0.1% to 1%): Edema

Frequency not reported: Death


Very common (10% or more): Infection (up to 22%), flu syndrome (up to 10%)

Common (1% to 10%): Abscess

Nervous system

Very common (10% or more): Headache (up to 34%)

Common (1% to 10%): Dizziness/vertigo, nervousness, somnolence, hypoesthesia, tremor, migraine, paresthesia, syncope, hypertonia, dysgeusia, exanthema, sedation

Uncommon (0.1% to 1%): Tinnitus, concentration impairment, coordination abnormal, dysarthria, memory impairment, restlessness, sedation, sleep disorder, slurred speech, coma

Rare (less than 0.1%): Disequilibrium, numbness

Frequency not reported: Convulsions

Postmarketing reports: Neonatal tremor, serotonin syndrome


QT prolongation has been observed. In clinical trials of buprenorphine (the active ingredient contained in Belbuca) buccal film (n=1590), post-baseline QTcF values of 450 to 480 milliseconds were observed in 2% of patients at doses up to 900 mcg every 12 hours. In a QT study in healthy subjects, therapeutic doses (10 mcg/hour transdermal patch) had no effect on the QTc interval, but higher doses (40 mcg/hour) were associated with a mean prolongation of 5.9 milliseconds.

During clinical trials, serial ECGs were collected to evaluate the effect of extended-release subcutaneous administration of buprenorphine on QT prolongation. Seven patients showed a greater than 60 msec increase QTc from baseline. One patient had a QTc greater than 500 msec. These QTc findings were reported as sporadic and transient and none led to aberrant ventricular rhythm. Review of ECG and adverse event data showed no evidence of syncope, seizure, or ventricular tachycardia or fibrillation.

Common (1% to 10%): Vasodilation, hypotension, peripheral edema, hypertension, palpitations

Uncommon (0.1% to 1%): Orthostatic hypotension, tachycardia, angina pectoris, flushing, bradycardia, cyanosis, , QT prolongation

Frequency not reported: Wenckebach block


Common (1% to 10%): Runny eyes, miosis, mydriasis, lacrimation disorder

Uncommon (0.1% to 1%): Dry eye, vision blurred, conjunctivitis

Rare (less than 0.1%): Eyelid edema, visual disturbance

Frequency not reported: Diplopia, visual abnormalities, amblyopia


Common (1% to 10%): Urinary tract infection, dysmenorrhea

Uncommon (0.1% to 1%): Urinary incontinence, urinary retention

Rare (less than 0.1%): Urinary hesitation, decreased erection, sexual dysfunction


Common (1% to 10%): Anorexia

Uncommon (0.1% to 1%): Dehydration, loss of appetite, weight decreased

Postmarketing reports: Neonatal feeding disorder


Common (1% to 10%): Lymphadenopathy


Uncommon (0.1% to 1%): Allergic reaction

Rare (0.01% to 0.1%): Anaphylactic responses

Very rare (less than 0.01%): Serious allergic reactions

Anaphylaxis has been reported with ingredients contained in the implant. Anaphylaxis has been reported with ingredients contained in extended-release subcutaneous injection.


Common (1% to 10%): Increased ALT, increased AST, increased gamma-glutamyl transferase (GGT)

Rare (less than 0.1%): Biliary colic

Frequency not reported: Hepatitis, jaundice, hepatic failure, hepatic necrosis, hepatorenal syndrome, hepatic encephalopathy, transaminases increased


Very common (10% or more): Implant site pain (13%), implant site pruritus (12%), implant site erythema (10%)

Common (1% to 10%): implant site hematoma, implant site hemorrhage, implant site edema, injection site pain, injection site pruritus, injection site erythema, injection site induration

Uncommon (0.1% to 1%): Injection site bruising, injection site swelling, injection site discomfort, injection site reaction, injection site cellulitis, injection site infection



Postmarketing reports: Adrenal insufficiency, androgen deficiency

Cases of androgen deficiency have been reported with chronic use of opioids. Adrenal insufficiency has been reported with opioid use, especially with use of 1 month or longer.

Editorial References and Review

Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.

Source: Drugs.com Belbuca (www.drugs.com/belbuca.html).

What pharmacies accept this discount program?

Rite Aid, Wal-Mart, Walgreens, CVS, Duane Reade, Target, Safeway, Kroger, K-mart, and all national and regional chains accept the card.

What if you didn’t find your pharmacy names above?

Search our pharmacy network on our homepage and medication search results.

What if the dosage, quantity, or drug name of the Belbuca coupon I downloaded is different from what I’m trying to fill right now?

Not to worry, you can use ANY USA RX downloaded coupon for any prescription medication. 

Is this a federal healthcare program, like Medicare or Medicaid?

No, USA Rx is not a federal healthcare program.

Does this prescription discount card work with my health insurance?

No, you must decide at the pharmacy either to use your Belbuca coupon or your prescription insurance coverage through your health insurance. You must also have a valid prescription to receive the discount price. In addition, compare the out of pocket costs from your health insurance and our discount.

Is this a drug manufacturer rebate?

No, this is not a rebate. These are discount coupons associated with USA Rx and our goal is to provide our customers with an option for low out of pocket costs. We are not associated with Biodelivery Sciences International, Inc.

Who is defined as eligible patients for the free Belbuca discount card?

Anyone in the United States and U.S. territories such as Puerto Rico are deemed eligible patients.

What company owns Belbuca?

Belbuca is owned by Biodelivery Sciences International, Inc. If you are looking for a free trial, a free 30-day trial card, a rebate, or an activated co-pay card for Belbuca, we recommend visiting the Biodelivery Sciences International, Inc. website.

Does this coupon work for brand name drug and the generic version?

Yes, both generic and brand prescription medication are covered by the coupon. Remember, any coupon can be applied to any prescription drug at a participating pharmacy and receive a discount with maximum savings.

Belbuca Prescription Savings Explained

FAQ Disclaimer: USA Rx LLC has a full endorsement of our prescription savings discount program. This product does not replace your insurance plan and it is not a rebate program. You may check the price of both your insurance plan (copay) and our patient assistance program. These are  easy steps to get the lowest average Belbuca cash price. USA Rx is not associated with Biodelivery Sciences International, Inc. Our affiliates use the “powered by USA Rx” symbol in marketing materials. If you have a medical condition and need assistance with figuring out your best option is for a discount program of prescription savings, please give us a call or drop us an email. Make sure to check your spam folder if you do no receive a response. To download card, visit our website. If you need medical help, please seek proper medical care as soon as possible. Check with your doctor about the accuracy of the information on the common version of Belbuca included on this page. Chat with your doctor or pharmacist about what dose of Belbuca pain reliever you should be taking, as well as all possible side effects such as severe pain. All cardholders adhere to our privacy policy and we use recent information to create our pricing estimates, which are subject to change. Prescription prices are subject to change.